Last updated on March 2019

Study for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients


Brief description of study

The purpose of this study is to compare the efficacy and safety of maribavir to valganciclovir for the treatment of cytomegalovirus (CMV) infection in asymptomatic hematopoietic stem cell transplant recipients.

Clinical Study Identifier: NCT02927067

Find a site near you

Start Over

CHU Angers

Angers Cedex 9, France
  Connect »

Birmingham Heartlands Hospital

West Midlands, United Kingdom
  Connect »

UCLA Medical Center

Los Angeles, CA United States
  Connect »

Westmead Hospital

Westmead, Australia
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

Dong-A University Hospital

Busan, Korea, Republic of
  Connect »

Texas Transplant Institute

San Antonio, TX United States
  Connect »

Hammersmith Hospital

London, United Kingdom
  Connect »

CHU de GRENOBLE

GRENOBLE Cedex 9, France
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

CHU de Li ge

Liège, Belgium
  Connect »

Henry Ford Health System

Detroit, MI United States
  Connect »

University of Minnesota

Minneapolis, MN United States
  Connect »

UMass Memorial Medical Center

Worcester, MA United States
  Connect »

Johns Hopkins Hospital

Baltimore, MD United States
  Connect »

Christie Hospital

Manchester, United Kingdom
  Connect »

Stanford University

Stanford, CA United States
  Connect »

Emory University

Atlanta, GA United States
  Connect »

University of Pennsylvania

Philadelphia, PA United States
  Connect »

University of Chicago

Chicago, IL United States
  Connect »

UZ Antwerpen

Wilrijk, Belgium
  Connect »

Hopital de Hautepierre

Strasbourg Cedex, France
  Connect »

H tel Dieu

Nantes, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.